Results 121 to 130 of about 2,864 (172)
Delamanid Resistance: Update and Clinical Management
Clinical Infectious Diseases, 2020 Abstract Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence.
Thi Van Anh Nguyen +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bedaquiline and delamanid in tuberculosis
Expert Opinion on Pharmacotherapy, 2015In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen against TB, intermittent drug use, errors in medical prescriptions, low quality of old TB drugs and ineffective TB control have led to the emergence of resistant TB.Two new drugs have gained ...
S. Esposito, S. Bianchini, F. Blasi
openaire +3 more sources
Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis
Tuberculosis, 2018Delamanid, a bicyclic nitroimidazooxazole, is effective against M. tuberculosis. Previous studies have shown that resistance to a bicyclic nitroimidazooxazine, PA-824, is caused by mutations in an F420-dependent bio-activation pathway. We investigated whether the same mechanisms are responsible for resistance to delamanid.
Masanori Kawasaki, Yongge Liu
exaly +3 more sources
Delamanid: First Global Approval
Drugs, 2014Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy.
Nicola J, Ryan, Jin Han, Lo
openaire +2 more sources
Delamanid in the treatment of multidrug-resistant tuberculosis
The International Journal of Tuberculosis and Lung Disease, 2016Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development. Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit with respect to short-term surrogate markers and long-term treatment outcomes, and it has ...
R, Gupta +4 more
openaire +2 more sources
Delamanid for Extensively Drug-Resistant Tuberculosis
New England Journal of Medicine, 2015Therapeutic options for extensively drug-resistant tuberculosis infection are limited. In this post-hoc analysis, a new drug, delamanid, shows some activity in the treatment of XDR-TB.
Rajesh, Gupta +5 more
openaire +2 more sources
Delamanid for the treatment of pulmonary multidrug resistant tuberculosis
Drugs of Today, 2015Out of a handful of new drugs currently in clinical trials for the treatment of tuberculosis, delamanid, a nitro-dihydro-imidazole derivative, has successfully emerged. Delamanid is a novel mycolic acid biosynthesis inhibitor that is equally potent against drug-sensitive as well as drug-resistant Mycobacterium tuberculosis.
R, Thakare +3 more
openaire +2 more sources